Targeting Mitochondrial Dysfunction

Our lead product, Imeglimin, is in Phase 3 development in Japan and has successfully completed Phase 2 development in the U.S. and EU.

View Candidate
Targeting Mitochondrial Dysfunction

Innovative Pipeline of First-In-Class Products

Our candidates are based on disease-modifying mechanisms of action that offer the potential for safer and more effective therapies for type 2 diabetes and NASH.

View Pipeline
Innovative Pipeline of First-In-Class Products

Backed by Strong Leadership

Our highly-experienced clinical and regulatory teams possess the know-how and experience to successfully develop products within our pipeline.

Meet Our Team
Backed by Strong Leadership

Latest News

Poxel Announces Participation at the H.C. Wainwright 3rd Annual NASH Investor Conference

Presentation will include an overview of Poxel’s two clinical-stage programs for the treatment of NASH LYON, France--(BUSINESS WIRE)-- POXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical…

Read this Press Release: Poxel Announces Participation at the H.C. Wainwright 3rd Annual NASH Investor Conference

Poxel Reports Financial Results for the Third Quarter and Nine Months 2019 and Provides Corporate Update

LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and…

Read this Press Release: Poxel Reports Financial Results for the Third Quarter and Nine Months 2019 and Provides Corporate Update

Poxel Announces Detailed Imeglimin Phase 3 TIMES 1 Results Presented at 55th Annual Meeting of the European Association for the Study of Diabetes

Imeglimin results featured in symposium session with leading diabetes expert Ralph DeFronzo, M.D., discussing preclinical and clinical data supporting safety and efficacy of Imeglimin in various patient populations…

Read this Press Release: Poxel Announces Detailed Imeglimin Phase 3 TIMES 1 Results Presented at 55th Annual Meeting of the European Association for the Study of Diabetes
Click here to show the previous slide Click here to show the next slide

Upcoming Events

Licensing Executives Society (LES) 2019 Annual Meeting

HC Wainwright 3rd Annual NASH Investor Conference

BioNetwork Partnering Summit

Gilbert Dupont NASH Conference

American Association for the Study of Liver Diseases (AASLD) poster presentation for PXL065

Bio-Europe

William Blair Boston Innovation Day

China Healthcare Summit 2019, The Bridge to Innovation

Jefferies Global Healthcare Conference

World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease

Click here to show the previous slide Click here to show the next slide